| Ytd | -11.64% | |
| 1y | 4.25% |
| Open | 15.78 | Prev Close | 15.62 | Low | 15.71 | High | 15.96 | Mkt Cap | 2.07B |
| Vol | 80.34K | Avg Vol | 220.18K | EPS | -1.27 | P/E | -12.51 | Forward P/E | 454.55 |
| Beta | 0.80 | Short Ratio | 17.15 | Inst. Own | 3.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 02-26 | 50-d Avg | 14.91 | 200-d Avg | 16.07 | 1yr Est | 35.00 |
MESO News
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let'
US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition propo
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader
Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust ear
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
U.S. stock futures down, Nasdaq 100 futures drop over 1%. ON Semi to acquire Synaptics, ON shares fa
Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Repo
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader
Stock News JPMorgan tops Q1 estimates: JPMorgan Chase (JPM) posted Q1 EPS of $5.94 on revenue of $50
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George bought 1,981,890 shares o
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 4,000,000 shares
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 2,324,072 shares
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification a
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and a
Mesoblast outlines commercial strategy to double net revenues as Ryoncil ® approaches US$100M net re
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Wednesday